Herbalife China

Herbalife Ltd. (NYSE: HLF) is up more than 40 percent in 2018, and investors can expect even more gains ahead, according to Citi. The Analyst Citi's Beth Kite upgraded Herbalife's stock rating from Neutral to Buy with a price target boosted from $85 to $114. The Thesis Multiple positive...

U.S. stocks declined as investors continue to question China's growth prospects following Monday's shocking report that its exports had tumbled in February. Certainly not helping investor sentiment is the fact that Crimea's parliament voted to declare independence from Ukraine. This weekend,...

Here's a look at the top tickers trending on StockTwits.com. La Jolla Pharmaceutical: Successful Phase 2 trial results Last night, La Jolla Pharmaceutical (NASDAQ: LJPC) reported that its Phase 2 trial of its GCS-100 chronic kidney disease drug “"met its primary efficacy endpoint of a...

Here's a look at the top tickers trending on StockTwits.com Ariad Pharmaceuticals: Buyout rumors persist On Friday, analysts at BMO Capital upgraded Ariad Pharmaceuticals (NASDAQ: ARIA) from Market Perform to Outperform with a price target raised to $14 from a previous $8. The analysts noted...

Major indices continued to plummet on Friday with no economic data released that could rejuvenate the market. Investors remain worried about a Chinese slowdown, a mixed-bag of corporate results on Wall Street and possible further tapering just around the corner as the Fed meets again next...

Stocks traded mostly lower today as investors digested a new set of earnings that were disappointing. A mixed housing data and a consumer sentiment coming in lower than expected was enough to tame the bulls as major indices finished the day mixed. Markets will be closed on Monday for Martin...